e-learning
resources
Virtual 2020
Tuesday, 08.09.2020
Diagnosis and management of asthma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Real-world treatment patterns of benralizumab therapy for patients with severe asthma
A. Gendron (Mississauga, Canada), N. Sriskandarajah (Mississauga, Canada), K. Johnston (Vancouver, Canada), K. Osenenko (Vancouver, Canada), S. Noorduyn (Mississauga, Canada)
Source:
Virtual Congress 2020 – Diagnosis and management of asthma
Session:
Diagnosis and management of asthma
Session type:
Oral Presentation
Number:
4646
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Gendron (Mississauga, Canada), N. Sriskandarajah (Mississauga, Canada), K. Johnston (Vancouver, Canada), K. Osenenko (Vancouver, Canada), S. Noorduyn (Mississauga, Canada). Real-world treatment patterns of benralizumab therapy for patients with severe asthma. 4646
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Real-world oral glucocorticoid-sparing effect of benralizumab in severe asthma
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Real-life effectiveness of anti-IL-5(-receptor) antibody treatment in patients with severe eosinophilic asthma
Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Year: 2019
Evolution of patients with severe asthma treated with mepolizumab
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma?
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Evaluation of therapeutic response to anti-IL5 treatment in severe eosinophilic asthma patients no responders to omalizumab
Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Year: 2019
The cost-efficacy of combined anti-inflammatory therapy in the treatment of children in severe persistent asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 134s
Year: 2003
Real-world treatment patterns of newly diagnosed patients with asthma and/or COPD
Source: Virtual Congress 2021 – Advances in asthma treatment
Year: 2021
Real-life impact of weight in severe eosinophilic asthma patients treated with benralizumab
Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies
Year: 2021
The response to combination therapy treatment regimens in severe/difficult-to-treat asthma
Source: Eur Respir J 2008; 32: 1237-1242
Year: 2008
Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma
Source: Eur Respir J, 55 (5) 1902259; 10.1183/13993003.02259-2019
Year: 2020
Add-on omalizumab therapy for patients with severe persistent allergic (IgE-mediated) asthma: identifying which patients to treat and which patients respond
Source: Eur Respir J 2006; 28: Suppl. 50, 440s
Year: 2006
Two therapy option in patients with uncontrolled asthma
Source: International Congress 2018 – Physiological and biological insights in asthma
Year: 2018
Cost analysis for patients with severe asthma receiving omalizumab treatment
Source: International Congress 2019 – Clinical aspects of airway diseases
Year: 2019
Severe asthma and biologic therapies during COVID-19: supporting patients care with home administration of mepolizumab and omalizumab
Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies
Year: 2021
Evaluating the efficacy of omalizumab in severe persistent asthma patients
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017
Omalizumab improves asthma control in patients receiving high-dose ICS and multiple other controller therapies and who have continuing impairment of lung function and asthma symptoms
Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities
Year: 2007
Multicolored magnetic-laser therapy in asthma patients
Source: Eur Respir J 2004; 24: Suppl. 48, 510s
Year: 2004
Efficacy of ruzam in the treatment of patients with mild-to-moderate asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 131s
Year: 2004
Which patients should be treated with anti-IgE?
Source: Eur Respir Rev 2007; 16: 85-87
Year: 2007
Effectiveness of combined therapy in patients with brittle asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 512s
Year: 2002
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept